Treatment targets in SLE: remission and low disease activity state

Research output: Contribution to journalArticleAcademicpeer-review

29 Citations (Scopus)


Treat-to-target strategies have changed the approach to management of many chronic conditions, with improvements in patient outcomes. The key to success of treat to target is the availability of validated treatment endpoints, which have been difficult to derive for SLE, a condition notorious for its heterogeneity. This review will focus on the development and validation of the definitions of remission in SLE framework and the lupus low disease activity state. Lupus low disease activity state is more attainable than remission, with a stepwise concentric relationship between the target states indicating increasing stringency. Both lupus low disease activity state and definitions of remission in SLE remission have been proven to be associated with reduction in disease flares, reduced risk of accrual of irreversible end organ damage, and improvement in patient reported outcomes. These endpoints have therefore provided the key for the development of a treat-to-target approach in clinical practice in SLE and for the design of future clinical trials.
Original languageEnglish
Pages (from-to)v19-v28
JournalRheumatology (Oxford, England)
Issue number5
Publication statusPublished - 1 Dec 2020


  • Lupus low disease activity state
  • Remission
  • SLE
  • Treat to target
  • Treatment endpoints

Cite this